Effect of Tołpa Peat Preparation on Some Immune Parameters in Healthy Volunteers. Preliminary Data
cohort Grade C 1993 n=16
Authors: Baj, Z., Zeman, K., Sułowska, Z., Majewska, E., Pokoca, L., Kocur, E.
Journal: Acta Poloniae Pharmaceutica 50 (6) : 481-489
PubMed: PMID 8067260
Key Findings
- Healthy volunteers took oral Tołpa Peat Preparation (TPP) at 50, 100, 300, or 600 mg/day for 14 days, 4 volunteers per dose
- Measured T-lymphocyte subsets, IL-1/IL-2 generation, IL-2 receptor expression, lymphocyte proliferation, monocyte TNF-alpha, and granulocyte superoxide production
- Considerable differences were found at higher TPP doses across several immune parameters
- The authors themselves caveat the small group size (4 per dose) and absence of a placebo group as reasons to treat the results as preliminary
The first human-dosing study of oral Tołpa Peat Preparation (TPP) — a specific, standardized peat-derived preparation, not peat in general — testing four dose levels against a panel of immune markers. Higher doses produced notable shifts in several parameters, but with only four volunteers per dose group and no placebo arm, the authors explicitly frame their own results as preliminary rather than conclusive. Abstract-only sourcing; no full text was located.
tppimmunomodulatoryhuman-studypreliminary